知镜 Cognispect · 医学文献与研究工作台

The CGRP-nociceptor axis in cancer: tumor-specific programs of immune evasion, stromal remodeling, and tumor growth.

Hua Y, Liu Y, Wang B, Liu Y, Tian X, Liu F, Tian Q, Yin F.
Frontiers in oncology · 2026-09-22 · PMID 42840415

文献摘要

Cancer neuroscience has established that peripheral nerves can shape tumor growth and antitumor immunity, although the underlying mechanisms vary across malignancies. Calcitonin gene-related peptide (CGRP), released mainly by peptidergic nociceptors and sensed through the CALCRL/RAMP1 receptor complex, is emerging as a recurrent mediator of tumor-nerve communication. This review synthesizes current evidence for CGRP signaling across tumor types. In melanoma and head and neck squamous cell carcinoma (HNSCC), CGRP can directly suppress tumor-infiltrating T cell activity. In lung adenocarcinoma, it acts through a macrophage-fibroblast relay that limits tertiary lymphoid structure assembly. In medullary thyroid cancer, tumor-associated CGRP is linked to abnormal dendritic cell development. In pancreatic ductal adenocarcinoma, nociceptor-derived CGRP participates in a reciprocal interaction with cancer-associated fibroblasts that lowers IL-15 and suppresses natural killer cells. Additional studies identify tumor-intrinsic outputs, including gastric tumor growth, CGRP-dependent cytoprotective autophagy in oral cancer, and RAMP1-dependent growth in gastrointestinal cancer models. Liver data currently support a role in fibrogenesis, while the relevance of this pathway to hepatocellular carcinoma remains unresolved. Together, these findings support a shared nociceptor-CGRP signaling system with tumor-specific cellular outputs. CGRP-pathway drugs and nociceptor-directed interventions therefore warrant tumor-specific translational studies, although anticancer efficacy remains predominantly preclinical.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。